Topic: escitalopram

Antidepressant drugs are beneficial for many of the symptoms of depression, but impairments in reward and motivation often remain or become worse. The effort-based foraging (EBF) and the effort-for-reward (EfR) tasks target different aspects of reward processing and motivation. This study investigated the effects of different antidepressants on effort-related decision-making (EfR) and motivation to engage with natural foraging (EBF). 2 cohorts of 16 and 24 C57bl/6J male mice were used in fully randomised, counterbalanced within-subject designs for acute pharmacological studies (escitalopram, v

Depressive disorders are the leading cause of the neuropsychiatric disparity, and the lack of understanding of the causes and treatment of these disorders progresses toward therapeutic failure. Current treatment approaches only provide symptomatic relief but fail to cure the underlying pathophysiology. The present study aimed to investigate the antidepressant effect of escitalopram (ESC) and galantamine (GAL) combination in vivo on a chronic unpredictable mild stress (CUMS)-induced depression in mice and further explored its mechanism of action around cAMP, BDNF-related neurotrophic signaling,

Dysregulation of serotonin (5-HT) transmission has been implicated as a factor in the development of depression. This study determined the effects of Tat on serotonin transporter (SERT), dynamic 5-HT release, and the effect of induction of Tat expression on mobility in the tail-suspension test (TST) in inducible Tat transgenic (iTat-tg) mice. Optimization of recombinant Tat1-86 (rTat1-86) concentration revealed a Ki of 7.2 nM for it inhibiting 5-HT uptake into mouse synaptosomes. SRI-32743 displayed a partial antagonism with 13 nM affinity and 69.5% Emax for inhibiting 5-HT uptake in CHO cells

Selective serotonin reuptake inhibitors (SSRI) are the most commonly prescribed class of antidepressants. However, SSRIs are frequently ineffective and precision medicine approaches are strongly needed to optimize treatment efficacy. DNA methylation levels of serotonin transporter (SLC6A4m) and tryptophan hydroxylase 2 (TPH2m) genes have been suggested as predictive biomarkers of antidepressant efficacy. In this study, we aimed to evaluate SLC6A4m/TPH2m biomarker potential and compare with previous findings in an independent cohort of N=77 patients with major depressive disorder who were treat